RightFit
RecruitingNot applicable

Advanced Fibrosis Detection for MASLD in Primary Care

Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests an alert in electronic health records that does not interrupt care. The alert helps primary care teams check the risk of liver scarring in people with MASLD, a condition where fat builds up in the liver. Primary care clinicians will also take part by giving feedback.

This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Patients must have MASLD listed as a diagnosis in their health record.
  • Type 2 diabetes is mentioned, but this rule is incomplete in the listing.
  • Doctors, physician assistants, and nurse practitioners who provide primary care during the study’s alert-testing phase can take part.

Who can't join

  • Patients with cirrhosis, which is severe liver scarring.
  • Patients with problems caused by cirrhosis, such as high blood pressure in veins near the liver or brain problems caused by liver disease.
  • Patients with liver cancer.
  • Patients who have had a liver transplant.
  • Patients who are pregnant.
  • No exclusion rules are listed for clinicians.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Patients Inclusion Criteria: * Patients with a diagnosis code for MASLD * Type 2 diabetes mellitus will Exclusion Criteria: * All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded. * pregnant women. Clinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices. Inclusion criteria: 1\. All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study. Exclusion criteria: None

Study sites (1)

SC